



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

中國神威藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(在開曼群島註冊成立之有限公司)

(Stock Code 股份代號：2877)

NOTIFICATION LETTER 通知信函

25 April 2025

Dear registered shareholder(s),

China Shineway Pharmaceutical Group Limited (the “Company”)

– Notice of Publication of 2024 Annual Report, Circular, Notice of the Annual General Meeting and Proxy Form (the “Current Corporate Communication”)

We hereby notify you that the English and Chinese versions of the Current Corporate Communication are now available on the Company’s website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk.

If you want to receive the Current Corporate Communication and future Corporate Communications in printed form, you may by giving at least 10 days’ notice in writing served on the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or send an email to ChinaShineway.ecom@computershare.com.hk, specifying your name, address and request to receive the Corporate Communications in printed form, or contact Customer Service Hotline of Share Registrar at (852) 2862 8555 from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday (excluding public holidays) and request to receive the Corporate Communications in printed form.

– Notice of Publication of Environmental, Social and Governance Report 2024 (the “ESG Report 2024”)

We hereby notify you that the English and Chinese versions of the ESG Report 2024 are now available in the “Investor Relations” section of the Company’s website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk. You may access the ESG Report 2024 through the website of the Company and that of HKEX.

Yours faithfully,

For and on behalf of

China Shineway Pharmaceutical Group Limited

Lee Bun Ching Terence

Company Secretary

Note: Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位登記股東：

中國神威藥業集團有限公司（「本公司」）

– 2024年年報、股東週年大會通函、股東週年大會通告及委任代表表格（「本次公司通訊」）之發佈通知

本公司謹此通知閣下本次公司通訊的英文及中文版本已登載於本公司網站(www.shineway.com.hk)及香港交易所披露易網站(www.hkexnews.hk)。

若閣下希望收取本次公司通訊及未來公司通訊的印刷版，可以提前至少10天以書面通知形式送達本公司香港辦事處股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓，或發送至電子郵件ChinaShineway.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求，或於週一至週五（公眾假期除外）上午9時正至下午6時正致電股份過戶處客戶服務熱線(852) 2862 8555並提出要求接收印刷版的公司通訊。

– 2024環境、社會及管治報告（「2024環境、社會及管治報告」）的刊發通知

本公司謹通知閣下，2024環境、社會及管治報告的英文及中文版本，現已登載於本公司網站（www.shineway.com.hk）「投資者關係」一欄，以及香港交易所披露易網站(www.hkexnews.hk)。閣下可於本公司及香港交易所披露易網站內閱覽2024環境、社會及管治報告。

代表
中國神威藥業集團有限公司
李品正
公司秘書
謹啟

2025年4月25日

附註： 公司通訊指公司向為其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a)董事會報告、年度帳目連同核數師報告以及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；和(f)委任代表書。